P
Pathos
Reimagining drug discovery and development through the lens of technology, with an AI intelligence platform
About Pathos
Pathos is a biotechnology company that operates at the intersection of artificial intelligence and oncology. The company's core mission is to accelerate the development of cancer drugs by leveraging a sophisticated platform that integrates vast amounts of oncology data, including genomic information.
Pathos utilizes advanced AI and machine learning algorithms to analyze this complex data, aiming to re-engineer the drug development process. This data-driven approach allows the company to identify and validate novel therapeutic targets and biomarkers, ultimately leading to more effective and personalized cancer treatments.
The company's business model is centered on collaborating with pharmaceutical and biotechnology partners to advance their oncology pipelines. By providing its AI-powered platform and insights, Pathos helps its clients to de-risk drug development, reduce timelines, and increase the probability of success for new cancer therapies. The company serves a clientele of researchers, drug developers, and clinicians in the oncology space.
Source: Dealroom company dataOpen roles
Pathos in the Chicago ecosystem
The Pathos office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
NEA
Lightbank
Revolution
Builders VC
Source: Dealroom Talent Intelligence.
Patents
1 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Pathos on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Pathos AI, BMS and Tempus team up on AI neuroscience discovery
Pathos strikes $2.2B Alphamab ADC licence and AstraZeneca pact to build AI-native oncology pipeline

